GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » VentriPoint Diagnostics Ltd (OTCPK:VPTDF) » Definitions » Capex-to-Revenue

VPTDF (VentriPoint Diagnostics) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is VentriPoint Diagnostics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

VentriPoint Diagnostics's Capital Expenditure for the three months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $0.05 Mil.

Hence, VentriPoint Diagnostics's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.00.


VentriPoint Diagnostics Capex-to-Revenue Historical Data

The historical data trend for VentriPoint Diagnostics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VentriPoint Diagnostics Capex-to-Revenue Chart

VentriPoint Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.11 - - -

VentriPoint Diagnostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VentriPoint Diagnostics's Capex-to-Revenue

For the Medical Devices subindustry, VentriPoint Diagnostics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VentriPoint Diagnostics's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's Capex-to-Revenue falls into.


;
;

VentriPoint Diagnostics Capex-to-Revenue Calculation

VentriPoint Diagnostics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.037
=0.00

VentriPoint Diagnostics's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.048
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VentriPoint Diagnostics  (OTCPK:VPTDF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


VentriPoint Diagnostics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of VentriPoint Diagnostics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


VentriPoint Diagnostics Business Description

Traded in Other Exchanges
Address
18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It develops applications for heart diseases and imaging modalities which includes congenital heart disease, left or right heart failure, and normal hearts. It sells its products in Canada and internationally.

VentriPoint Diagnostics Headlines

From GuruFocus